Breast Cancer

Pathologic Complete Response to Neoadjuvant Chemotherapy May Guide Escalation and De-escalation Treatment Strategies in Localized Breast Cancer

Phoebe Starr

February 2019, Vol 9, No 2 - Breast Cancer

Achieving pathologic complete response (pCR) after neoadjuvant chemotherapy correlates with significantly improved event-free survival (EFS) and overall survival (OS) in patients with localized breast cancer, according to the results of a large comprehensive meta-analysis presented at the 2018 San Antonio Breast Cancer Symposium. [ Read More ]

Supervised Exercise During Chemotherapy Improves Cardiovascular Function in Women with Breast Cancer

Phoebe Starr

February 2019, Vol 9, No 2 - Breast Cancer

A 12-month supervised exercise program improved cardiovascular function in women receiving adjuvant chemotherapy for breast cancer, including anthracyclines and taxanes. By contrast, cardiovascular function decreased among women with breast cancer who did not exercise according to the program guidelines. These results of a randomized clinical trial were presented at the 2018 San Antonio Breast Cancer Symposium. [ Read More ]

5-mg Tamoxifen as Effective as 20 mg Daily in Early Localized Breast Cancer

Phoebe Starr

January 2019, Vol 9, No 1 - Breast Cancer

The large, randomized TAM-01 clinical trial demonstrated that 5 mg daily of tamoxifen for 3 years halved the risk for recurrence of breast intraepithelial neoplasia—atypical ductal hyperplasia, ductal carcinoma in situ (DCIS), and lobular carcinoma in situ—in women after surgery and reduced the risk for new contralateral breast cancer by 75% compared with placebo. [ Read More ]

Talzenna Approved for HER2-Negative, Locally Advanced Breast Cancer with Germline BRCA Mutations

December 2018, Vol 8, No 12 - Breast Cancer, FDA Approvals, News & Updates

On October 16, 2018, the FDA approved talazoparib (Talzenna; Pfizer), a poly (ADP-ribose) polymerase (PARP) inhibitor, for the treatment of patients with HER2-­negative, locally advanced or metastatic breast cancer and deleterious or suspected deleterious germline BRCA mutation, as identified by an FDA-approved test. [ Read More ]

Chemotherapy Can Be Spared in Many Patients with Early Breast Cancer: Devil Is in the Details

Phoebe Starr

August 2018, Vol 8, No 8 - Breast Cancer

One of the most important studies presented at ASCO 2018 showed that endocrine therapy alone was noninferior to endocrine therapy plus chemotherapy in women with estrogen receptor (ER)-positive, HER2-negative, node-negative early-stage breast cancer and an intermediate risk score (score, 11-25) on the Oncotype DX gene-expression assay for breast cancer. [ Read More ]

Acquired HER2 Mutations in Metastatic Breast Cancer Confer Resistance to ER-Directed Therapy

Phoebe Starr

June 2018, Vol 8, No 6 - Breast Cancer

Metastatic estrogen receptor (ER)-positive breast cancer responds well to anti-ER therapies, but eventually resistance occurs and the drugs fail to work. A new study presented at the 2018 AACR meeting suggests that HER2 mutations can be acquired during metastatic cancer and their development represents a previously unreported mechanism of resistance to treatment. This resistance can be overcome by the irreversible HER2 inhibitor neratinib (Nerlynx). [ Read More ]

Verzenio (Abemaciclib) a New CDK4/CDK6 Inhibitor Approved for HR-Positive, HER2-Negative Advanced or Metastatic Breast Cancer

Loretta Fala

2018 Third Annual Oncology Guide to New FDA Approvals - Breast Cancer, FDA Approvals, News & Updates

Breast cancer affects more women than any other type of cancer, and represents 15% of all new cancer cases in the United States. A total of 252,710 new breast cancer cases were estimated to be diagnosed in 2017, and more than 40,600 deaths. The prognosis worsens for patients with locally advanced breast cancer and even more so for those with metastatic disease. [ Read More ]